Press Releases

Research and Markets: Key Findings from Treatment Algorithms: Alzheimer's Disease

DUBLIN--(BUSINESS WIRE)-- Research and Markets ( has announced the addition of Decision Resources, Inc's new report "Key Findings from Treatment Algorithms: Alzheimer's Disease" to their offering.

Alzheimer's disease (AD) is a debilitating neurodegenerative disease that causes an inexorable worsening of cognitive impairment, affecting memory loss in particular, as well language, behavior, and higher function. At present, there are no therapies to stop, prevent, or reverse the progression of AD.

In the absence of such disease-modifying drugs, AD is treated with therapies that address the cognitive complaints of the disease, namely the acetylcholinesterase inhibitors (AChEIs) donepezil (Eisai/Pfizer's Aricept, Aricept orally disintegrating tablet (ODT), Aricept 23, generics), rivastigmine (Novartis's Exelon/Exelon Patch, generics), and galantamine (Ortho McNeil Janssen's Razadyne/Razadyne ER, generics) and the NMDA receptor antagonist memantine (Forest Laboratories' Namenda). Off-label prescribing of antidepressants and antipsychotics to treat the depressive and behavioral symptoms, respectively, commonly associated with AD is also routine practice.

As of late 2010, generic formulations of all oral AChEIs were available. Donepezil, historically the patient share leader in AD, will continue to be the dominant AChEI following Aricept's loss of patent protection in November 2010; we do not expect any current therapy to challenge donepezil's dominant position now that generic formulations of that drug are available.

Experts interviewed by Decision Resources increasingly report the concomitant use of Namenda and an AChEI among AD patients, a trend mirrored in this analysis. Using patient-level claims data, this report determines the share of each currently marketed drug by line of therapy, evaluates therapy flow, and analyzes why key drugs are chosen over others.

Key Topics Covered:

1. Background

a) Publication Update

b) Report Contents and Features

c) Current Practice Guidelines

d) Key U.S. Market Events Influencing Treatment Selection

2. Key Findings for Newly Diagnosed Patients

a) Executive Summary

b) Graphical Views

3. Key Findings for Recently Treated Patients

a) Executive Summary

b) Graphical Views

4. Key Findings by Product

a) Donepezil (Eisai/Pfizer's Aricept, generics); Donepezil ODT (Aricept ODT,

generics); Aricept

b) Forest Laboratories' Namenda (memantine)

c) Novartis' Exelon patch (rivastigmine patch)

d) Galantamine (Ortho McNeil Janssen's Razadyne/Razadyne ER, generics)

5. Appendix: Methodology

For more information visit

Source: Decision Resources, Inc

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices, Pharmaceuticals, Central Nervous System

Source: Research and Markets